Shanghai Henlius Biotech disclosed preclinical findings for E-688 (HLX-316), an engineered human sialidase enzyme fused to an anti–B7-H3 nanobody. The approach is designed to improve tumor desialylation in order to enhance both innate and adaptive antitumor immune activity. The report says E-688 improved desialylation, durability, and efficacy in vitro and in vivo while maintaining a safe profile in preclinical testing. It positions the candidate as an immune-modulating strategy paired to B7-H3 tumor expression. For oncology platform builders, the translational bet is that remodeling the tumor glycan landscape can overcome immune evasion mechanisms tied to hypersialylation. The next gating items will be dose selection and how the construct performs across B7-H3 expression patterns as the program approaches further study phases.